Zentalis Pharmaceuticals Inc logo

Zentalis Pharmaceuticals Inc

1
NAS:ZNTL (USA)   Ordinary Shares
$ 4.73 -0.5 (-9.52%) 11:08 PM EST
At Loss
P/B:
0.73
Market Cap:
$ 335.89M
Enterprise V:
$ -110.47M
Volume:
2.80M
Avg Vol (2M):
1.35M
Trade In:
Volume:
2.80M
At Loss
Avg Vol (2M):
1.35M

Business Description

Zentalis Pharmaceuticals Inc logo
Zentalis Pharmaceuticals Inc
NAICS : 325411 SIC : 2833
ISIN : US98943L1070

Share Class Description:

ZNTL: Ordinary Shares
Description
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
Name Current Vs Industry Vs History
Cash-To-Debt 11.47
Equity-to-Asset 0.82
Debt-to-Equity 0.09
Debt-to-EBITDA -0.2
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -0.34
Distress
Grey
Safe
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 21.21
9-Day RSI 19.49
14-Day RSI 21.12
6-1 Month Momentum % -19.02
12-1 Month Momentum % -60.96

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 9.19
Quick Ratio 9.19
Cash Ratio 8.92

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.9
Shareholder Yield % -73.5

Financials (Next Earnings Date:2024-08-09 Est.)

ZNTL's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ZNTL

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Zentalis Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 40.56
EPS (TTM) ($) -3.33
Beta 1.74
Volatility % 74.79
14-Day RSI 21.12
14-Day ATR ($) 1.002863
20-Day SMA ($) 9.5015
12-1 Month Momentum % -60.96
52-Week Range ($) 3.9301 - 29.54
Shares Outstanding (Mil) 71.01

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Zentalis Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Zentalis Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Zentalis Pharmaceuticals Inc Frequently Asked Questions

What is Zentalis Pharmaceuticals Inc(ZNTL)'s stock price today?
The current price of ZNTL is $4.73. The 52 week high of ZNTL is $29.54 and 52 week low is $3.93.
When is next earnings date of Zentalis Pharmaceuticals Inc(ZNTL)?
The next earnings date of Zentalis Pharmaceuticals Inc(ZNTL) is 2024-08-09 Est..
Does Zentalis Pharmaceuticals Inc(ZNTL) pay dividends? If so, how much?
Zentalis Pharmaceuticals Inc(ZNTL) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1